Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis.

BACKGROUND The role of fluorodeoxyglucose (FDG)-PET imaging for diagnosing malignant pleural effusions is not well defined. The aim of this study was to summarize the evidence for its use in ruling in or out the malignant origin of a pleural effusion or thickening. METHODS A meta-analysis was conducted of diagnostic accuracy studies published in the Cochrane Library, PubMed, and Embase (inception to June 2013) without language restrictions. Two investigators selected studies that had evaluated the performance of FDG-PET imaging in patients with pleural effusions or thickening, using pleural cytopathology or histopathology as the reference standard for malignancy. Subgroup analyses were conducted according to FDG-PET imaging interpretation (qualitative or semiquantitative), PET imaging equipment (PET vs integrated PET-CT imaging), and/or target population (known lung cancer or malignant pleural mesothelioma). Study quality was assessed using Quality Assessment of Diagnostic Accuracy Studies-2. We used a bivariate random-effects model for the analysis and pooling of diagnostic performance measures across studies. RESULTS Fourteen non-high risk of bias studies, comprising 407 patients with malignant and 232 with benign pleural conditions, met the inclusion criteria. Semiquantitative PET imaging readings had a significantly lower sensitivity for diagnosing malignant effusions than visual assessments (82% vs 91%; P = .026). The pooled test characteristics of integrated PET-CT imaging systems using semiquantitative interpretations for identifying malignant effusions were: sensitivity, 81%; specificity, 74%; positive likelihood ratio (LR), 3.22; negative LR, 0.26; and area under the curve, 0.838. Resultant data were heterogeneous, and spectrum bias should be considered when appraising FDG-PET imaging operating characteristics. CONCLUSIONS The moderate accuracy of PET-CT imaging using semiquantitative readings precludes its routine recommendation for discriminating malignant from benign pleural effusions.

[1]  R. Hustinx,et al.  18F-FDG PET imaging in assessing exudative pleural effusions , 2006, Nuclear medicine communications.

[2]  K. Azuma,et al.  Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease , 2010, Japanese Journal of Radiology.

[3]  Jin Woong Indeterminate pleural metastasis on contrast-enhanced chest CT in non-small cell lung cancer: improved differential diagnosis , 2012 .

[4]  R. Coleman,et al.  FDG PET of pleural effusions in patients with non-small cell lung cancer. , 2000, AJR. American journal of roentgenology.

[5]  R. Louis,et al.  Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. , 2004, Chest.

[6]  J. M. Porcel,et al.  Pearls and myths in pleural fluid analysis , 2011, Respirology.

[7]  K. Uematsu,et al.  Clinical implications of 18 F-fluorodeoxyglucose positron emission tomography / computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma , 2011 .

[8]  F. Fazio,et al.  18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study. , 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[9]  A. Alavi,et al.  Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. , 1998, Chest.

[10]  U. Waheed,et al.  Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. , 2002, Chest.

[11]  H. Biersack,et al.  Impact of Dual-Time-Point F-18 FDG PET/CT in the Assessment of Pleural Effusion in Patients With Non-Small-Cell Lung Cancer , 2011, Clinical nuclear medicine.

[12]  John O. Prior,et al.  Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the assessment of pleural abnormalities in cancer patients: a systematic review and a meta-analysis. , 2014, Lung Cancer.

[13]  J. Monteil,et al.  Assessment of 18F-fluorodeoxyglucose dual-head gamma camera in asbestos lung diseases , 2004, European Respiratory Journal.

[14]  A. Alavi,et al.  Potential of Dual Time Point FDG-PET Imaging in Differentiating Malignant from Benign Pleural Disease , 2009, Molecular Imaging and Biology.

[15]  H. Schoellnast,et al.  Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET. , 2004, Radiology.

[16]  K. Bakır,et al.  The role of FDG PET-CT in differential diagnosis of pleural pathologies. , 2012, Revista espanola de medicina nuclear e imagen molecular.

[17]  U. Metser,et al.  Differentiation Between Malignant and Benign Pleural Effusion in Patients With Extra-Pleural Primary Malignancies: Assessment With Positron Emission Tomography-Computed Tomography , 2005, Investigative radiology.

[18]  H. Çiftçi,et al.  The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. , 2009, The Thoracic and cardiovascular surgeon.

[19]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[20]  M. Metintaş,et al.  Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Y. Nishiyama,et al.  Dual time point FDG PET for evaluation of malignant pleural mesothelioma , 2009, Nuclear medicine communications.

[22]  R. Hustinx,et al.  Contribution of positron emission tomography in pleural disease. , 2010, Revue des maladies respiratoires.

[23]  T. Nakano,et al.  Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma. , 2012, Experimental and therapeutic medicine.

[24]  J. M. Porcel,et al.  Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. , 2014, Archivos de bronconeumologia.

[25]  Kyoungjune Pak,et al.  Predictive Value of F-18 FDG PET/CT for Malignant Pleural Effusion in Non-Small Cell Lung Cancer Patients , 2011, Oncology Research and Treatment.

[26]  S. Treves,et al.  Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  John O. Prior,et al.  Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis. , 2014, Academic radiology.

[28]  K. Uematsu,et al.  Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma. , 2011, Oncology reports.

[29]  A. Dowlati,et al.  Evaluation of pleural diseases with FDG-PET imaging: preliminary report. , 1997, Thorax.

[30]  H. Groen,et al.  PET for the evaluation of pleural thickening observed on CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  John O. Prior,et al.  18F-fluorodeoxyglucose PET/CT findings in pleural effusions of patients with known cancer , 2012, Nuklearmedizin.

[32]  T. Turkington,et al.  A systematic review of the factors affecting accuracy of SUV measurements. , 2010, AJR. American journal of roentgenology.

[33]  Xue-Ning Yang,et al.  PET/CT鉴别肺癌中胸腔积液性质的临床价值 , 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[34]  J. M. Porcel,et al.  Etiología del derrame pleural: análisis de más de 3.000 toracocentesis consecutivas , 2014 .

[35]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[36]  C. Dooms,et al.  Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging--initial experience. , 2012, Radiology.